Immunovant, Inc. (IMVT) - Dilution Analysis

10-K filing | 205.3M shares outstanding

10-Q filing | 173.6M shares outstanding

10-Q filing | 170.9M shares outstanding

10-K filing | 170.9M shares outstanding

10-Q filing | 169.9M shares outstanding

8-K filing: Immunovant, Inc. entered into a share purchase agreement with institutional accredited investors to sell 22,500,000 shares of common stock at $20.00 per share, with gross proceeds expected to be approximately $450 million, in a private placement expected to close on or about January 15, 2025. ($450.0M proceeds)

10-Q filing | 146.5M shares outstanding

10-Q filing | 146.1M shares outstanding

10-K filing | 138.1M shares outstanding

10-Q filing | 144.5M shares outstanding

10-Q filing | 131.2M shares outstanding

10-Q filing | 130.5M shares outstanding

10-K filing | 123.1M shares outstanding

10-Q filing | 128.6M shares outstanding

10-Q filing | 116.6M shares outstanding

10-Q filing | 116.6M shares outstanding

10-K filing | 109.7M shares outstanding

10-Q filing | 115.0M shares outstanding

10-Q filing | 109.1M shares outstanding

10-Q filing | 115.0M shares outstanding

8-K filing: Immunovant, Inc. entered into a share purchase agreement with Roivant Sciences Ltd., where Immunovant agreed to issue and sell 17,021,276 shares of Immunovant common stock to Roivant at a price of $11.75 per share, resulting in gross proceeds of $200.0 million for Immunovant. ($200.0M proceeds)

10-K filing | 98.0M shares outstanding

10-Q filing | 98.0M shares outstanding

S-3 filing: The filing is an S-3 form for an at-the-market offering of common stock with an aggregate sale price of up to $150,000,000. The company intends to use the net proceeds from this offering to advance the development of their product candidate, IMVT-1401, and for working capital and general corporate purposes.

10-Q filing | 97.9M shares outstanding

S-1 filing: The company is offering 4,300,000 shares of common stock at a price of $35.00 per share.

10-Q filing | 81.8M shares outstanding

10-K filing | 81.8M shares outstanding

S-1 filing: Health Sciences Acquisitions Corporation proposes an initial public offering of 10,000,000 units at $10.00 per unit, and a private placement of 10,000,000 warrants at $0.50 per warrant. IMVT is offering 6,500,000 shares of common stock.

S-1/A filing: The selling stockholders may offer and sell from time to time up to 11,389,969 shares of our common stock, and up to 5,750,000 shares of common stock that are issuable upon the exercise of outstanding warrants.

S-1/A filing: The selling stockholders may offer and sell from time to time up to 11,389,969 shares of our common stock and up to 5,750,000 shares of common stock that are issuable by us upon the exercise of outstanding warrants that were previously registered.

S-1/A filing: The selling stockholders may offer and sell from time to time up to 11,389,969 shares of our common stock, and this prospectus relates to the offer and sale of up to 5,750,000 shares of common stock that are issuable by us upon the exercise of outstanding warrants that were previously registered.

10-Q filing | 54.7M shares outstanding

S-1 filing: The selling stockholders may offer and sell from time to time up to 66,342,874 shares of common stock, and this prospectus relates to the offer and sale of up to 5,750,000 shares of common stock that are issuable upon the exercise of outstanding warrants.